Comprehensive registry of lymphoproliferative disorders and outcomes
Official title: A Comprehensive Register Of Lymphoproliferative Disorders (ReLy)
Run by Fondazione IRCCS Policlinico San Matteo di Pavia · NCT07519356 · Data updated 2026-11-12
This project will test how treatments, patient health, and genetic features affect 10-year survival in adults with lymphoproliferative disorders.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 9000 (estimated) |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia Academic / other |
| Locations | 1 site (Pavia, Lombardy) |
| Status | Recruiting |
| Started | June 9, 2022 |
| Main results expected | December 30, 2030 |
| Study ends | December 30, 2030 |
| Registry record updated | April 9, 2026 |
| Trial ID | NCT07519356 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (age ≥18) diagnosed with or treated for lymphoproliferative disorders who can provide informed consent, or whose data are covered by institutional consent for retrospective inclusion, are eligible.
✕Probably not a fit
Patients seeking direct therapeutic benefit may not gain immediate medical benefit because this is an observational data registry, and those unable to provide informed consent are excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational registry enrolls adults with lymphoproliferative disorders, collecting retrospective and prospective clinical, treatment, and outcome data with long-term follow-up. The primary outcome is 10-year overall survival, and secondary objectives include documenting comorbidities, fitness, treatment choices, adverse events (including tumor lysis syndrome), and effectiveness of newer therapies such as chemo-free regimens, targeted drugs, and cell therapies. Investigators will correlate clinical and biological factors, including genotype and phenotype, with progression, relapse, and treatment discontinuation to identify optimal treatment sequences for relapsed or refractory cases. The registry is conducted at Fondazione IRCCS Policlinico San Matteo in Pavia, Lombardy, and aims to compare real-world effectiveness and safety across therapies.
Why it matters
Potential benefit: If successful, the registry could help doctors choose safer, more effective treatment sequences and improve long-term outcomes for patients.
How similar studies have gone: Other national and international lymphoma registries have improved understanding of outcomes and treatment patterns, but comprehensive integration of genotype data with newer targeted and cell therapies and treatment-sequence analysis remains relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients ≥ 18 years diagnosed with and/or treated for lymphoproliferative disorders. * Prospective patients (or their or legal guardians) who have the ability to understand and be willing to sign a written informed consent document * Retrospective patients who have signed the institutional document allowing the use of their data for research on their disease Exclusion Criteria: * Patients who are unable to understand informed consent document
Where it's running
-
Fondazione IRCCS Policlinico San Matteo
Pavia, Lombardy, Italy Recruiting
Study contacts
- Study coordinator: Luca Arcaini
- Email: l.arcaini@smatteo.pv.it
- Phone: 0382501284
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using special T cells to treat EBV-positive lymphoma
This study is testing a new treatment using special T cells to help people with EBV-positive Hodgkin's or non-Hodgkin lymphoma fight their cancer.
-
Epstein-Barr virus–positive T/NK-cell lymphoproliferative diseases in large patient groups
This study follows patients with EBV-positive T/NK-cell disorders to see how they present, what treatments are used, and how they respond over time.
-
Registry for individuals with T-cell lymphoma
This study is gathering information from people with T-cell lymphoma to help researchers learn more about the disease and improve treatments.
-
Treatment for Epstein-Barr Virus-Associated Lymphoproliferative Disease After Transplant
This study is testing a new treatment called tabelecleucel for patients with a specific type of cancer related to Epstein-Barr virus who haven't improved with other therapies after receiving a transplant.
-
Chemogenomic profiling for blood cancers
This project will test whether detailed genetic and molecular profiling of bone marrow, blood, or tissue samples can better characterize diagnosis and relapse for people with suspected or known blood cancers.
-
Multi-omics testing for blood and bone marrow cancers
This project will test a multi-omics lab approach on bone marrow, blood, biopsy and other fluid samples from people with suspected or known hematologic cancers to see if it can better characterize their disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.